Aethlon Medical Q1 Operating Expenses Fall 12%, Phase 1 Dosing Advances
AEMD is trading near its 52-week low of $2.625 (13% above the low) on light trading volume (0.1× avg).
Summary
Aethlon Medical's fiscal Q1 operating expenses dropped 12% year-over-year, driven by lower professional fees and reduced G&A and preclinical research costs, narrowing its operating loss. The company also dosed the first participant in the final cohort of its Phase 1 oncology study for Hemopurifier and reported preliminary biomarker signals supporting continued evaluation. With $4.9 million in cash at quarter-end and a $4.0 million post-quarter raise, management expects the runway to extend at least 12 months. This follows the 8-K filed earlier today reporting Q1 results and the recent 1-for-5 reverse split to maintain Nasdaq compliance. The clinical progress and cost discipline are modest positives, but the company remains pre-revenue with a going-concern history.
At the time of this announcement, AEMD was trading at $2.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $2.63 to $137.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.